Bevacizumab
- Generic Name
- Bevacizumab
- Brand Names
- Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216974-75-3
- Unique Ingredient Identifier
- 2S9ZZM9Q9V
- Background
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...
- Indication
As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...
- Associated Conditions
- Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Associated Therapies
- First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 65
- Registration Number
- NCT06540261
- Locations
- 🇯🇵
Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
🇯🇵Kurashiki Central Hospital, Kurashiki, Okayama, Japan
🇯🇵Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 54
- Registration Number
- NCT06509906
- Locations
- 🇺🇸
Sarah Cannon Research Institute at Health One, Denver, Colorado, United States
🇦🇺St George Private Hospital, Kogarah, Australia
🇦🇺Peter MacCallum Cancer Centre - Use the one with Account 2 VCCC, Parkville, Australia
A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization
- Conditions
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 113
- Registration Number
- NCT06503250
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou City, China
🇨🇳The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
🇨🇳Tianjin First Central Hospital, Tianjin, China
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Chipscreen Biosciences, Ltd.
- Target Recruit Count
- 430
- Registration Number
- NCT06497985
- Locations
- 🇨🇳
Rui-Hua Xu, Guangzhou, Guangdong, China
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 32
- Registration Number
- NCT06496971
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 130
- Registration Number
- NCT06493760
- Locations
- 🇨🇳
Liu Tianshu, Shanghai, Shanghai, China
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 42
- Registration Number
- NCT06487715
- Locations
- 🇨🇳
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Institut Cancerologie de l'Ouest
- Target Recruit Count
- 84
- Registration Number
- NCT06471465
- Locations
- 🇫🇷
Institut de Cancérologie de l'Ouest, Saint-Herblain, France
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
- Conditions
- Interventions
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT06469281
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey, United States
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT06448364
- Locations
- 🇵🇷
Hospital Oncológico Dr. Isaac González-Martinez, Rio Piedras, Puerto Rico
🇺🇸NEXT Oncology, San Antonio, Texas, United States
🇵🇷Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.